Señales en vivo de RUBY | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 dic 2023 @ 15:49):

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases...

Stats
Volumen de hoy	755 858
Volumen promedio	99 535.00
Capitalización de mercado	5.16M
EPS	$0 ( 2024-02-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0286
ATR14	$0.00200 (3.51%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-24	Appelhans Dannielle	Sell	10 385	Common Stock
2023-02-01	Cagnoni Pablo J	Sell	8 448	Common Stock
2023-01-31	Appelhans Dannielle	Sell	7 500	Restricted Stock Units
2023-01-31	Appelhans Dannielle	Buy	7 500	Common Stock
2023-02-01	Appelhans Dannielle	Sell	3 878	Common Stock

INSIDER POWER
20.47
Last 96 transactions
Buy: 4 525 378 \| Sell: 349 777

Volumen Correlación

Largo: 0.54 (weak)

Corto: 0.36 (neutral)

Signal:(87.518) Neutral

Rubius Therapeutics Inc Correlación

10 Correlaciones Más Positivas
DFPH	0.979
VOSOU	0.978
LWAC	0.97
LWACU	0.968
GSMG	0.961
AGBA	0.943
MRAC	0.939
PPGHU	0.913
ALVR	0.895
ARQT	0.889

10 Correlaciones Más Negativas
ESAC	-0.962
CTAC	-0.961
MCAE	-0.952
CMLT	-0.918
BCYP	-0.914
KURI	-0.894
ICLK	-0.891
GIAC	-0.889
MACQU	-0.882
GLADL	-0.882

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rubius Therapeutics Inc Correlación - Moneda/Commodity

-0.07
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.69
( moderate negative )

-0.48
( neutral )

Rubius Therapeutics Inc Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-2.56

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-2.56

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.23

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.08

Financial Reports:

No articles found.

Rubius Therapeutics Inc

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.